创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: iHuPBMC-OncVax Model Features

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-04 14:23
  • Views:

(Summary description)With the continuous development of medical science and technology, research on cancer treatment has made significant breakthroughs. The iHuPBMC-OncVax model platform of InnoModels Biotechnology has attracted widespread attention. This vaccine platform has many unique features that bring new hope for cancer treatment

InnoModels: iHuPBMC-OncVax Model Features

(Summary description)With the continuous development of medical science and technology, research on cancer treatment has made significant breakthroughs. The iHuPBMC-OncVax model platform of InnoModels Biotechnology has attracted widespread attention. This vaccine platform has many unique features that bring new hope for cancer treatment

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-04 14:23
  • Views:
Information

With the continuous development of medical science and technology, research on cancer treatment has made significant breakthroughs. The iHuPBMC-OncVax model platform of InnoModels Biotechnology has attracted widespread attention. This vaccine platform has many unique features that bring new hope for cancer treatment.
Highly personalized:
The iHuPBMC-OncVax platform is prepared using the patient's immune cells, and personalized vaccines are tailored to the patient's specific situation. This highly personalized preparation can effectively improve the therapeutic effect of the vaccine on patients.
Dual Target Strike:
The iHuPBMC-OncVax vaccine platform employs two targets, which can ** both attack tumor cells by the immune system and inhibit the growth of tumor cells. This dual-target strike strategy can effectively improve the efficacy of the vaccine.

 


Innovative Preparation Process:
The iHuPBMC-OncVax vaccine platform employs an innovative preparation process that combines the patient's immune cells with tumor antigens to produce a vaccine that targets the patient's specific tumor. This process ensures a high degree of vaccine personalization and improves vaccine stability.
Wide range of application:
The iHuPBMC-OncVax vaccine platform is applicable to the treatment of a wide range of cancers, such as lung cancer, breast cancer and melanoma. This wide range of applicability makes this vaccine platform have a broad market prospect.
Remarkable clinical results:
According to the results of clinical trials, iHuPBMC-OncVax vaccine platform has achieved remarkable results in the treatment of various cancers. After using this vaccine, the condition of some patients has been effectively controlled and their survival period has been significantly extended.
In conclusion, iHuPBMC-OncVax is a breakthrough cancer vaccine platform from InnoModels Biotechnology, which brings new hope for cancer treatment with its highly personalized, dual-targeted strike, innovative preparation process, broad applicability and remarkable clinical efficacy. With further research and application of this vaccine platform, it is believed that more cancer patients will benefit.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司